fouremm-

I'm sure you're right about the importance of analysts' coverage. With epigenetics being such a new field, investors can't assess the risks or potential. So they keep away. Of course, it's also a new field to analysts. So perhaps that's why they prefer to stay away too! 
I don't need an analyst to tell me ABL has a good future. If I had more cash I'd be buying buckets of shares at this ridiculously low price.